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Abstract
The use of autologous cells harvested and subsequently transplanted in an intraoperative
environment constitutes a new approach to promote regeneration. Usually cells are isolated
by selection methods such as fluorescence- or magnetic- activated cell sorting with residual
binding of the antibodies or beads. Thus, cell-based therapies would benefit from the devel-
opment of new devices for cell isolation that minimally manipulate the target cell population.
In the clinic, 5 to 10 percent of fractures do not heal properly and CD31+ cells have been
identified as promising candidates to support bone regeneration. The aim of this project was
to develop and prototype a simple system to facilitate the enrichment of CD31+ cells from
whole blood. After validating the specificity of a commercially available aptamer for CD31,
we combined this aptamer with traditional magnetic bead strategies, which led to enrich-
ment of CD31+ cells with a purity of 91±10%. Subsequently, the aptamer was attached to
agarose beads (Ø = 100–165 um) that were incorporated into a column-based system to
enable capture and subsequent release of the CD31+ enriched cells. Different parameters
were investigated to allow a biophysical-based cell release from beads, and a simple mixing
was found sufficient to release initially bound cells from the optimized column without the
need for any chemicals that promote disassociation. The system led to a significant enrich-
ment of CD31+ cells (initial population: 63±9%, released: 87±3%) with excellent cell viability
(released: 97±1%). The composition of the released CD31+ fraction indicated an enrich-
ment of the monocyte population. The angiogenic and osteogenic potential of the released
cell population were confirmed in vitro. These results and the simplicity of this system high-
light the potential of such approach to enable cell enrichment strategies in intraoperative
settings.
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Introduction
In order for cell therapies to be translated from the bench to the clinic, they must follow good
manufacturing practice guidelines and be approved by regulatory agencies. In the case of exog-
enous cell therapies, significant regulatory constraints on cell isolation and in vitro expansion
procedures to ensure the quality and safety of the resultant product lead to high costs [1,2]. An
alternative approach to obtain a sufficient number of cells is cytokine-based cell mobilization,
such as the use of granulocyte colony-stimulating factor for the mobilization of hematopoietic
stem cells [3]. However, not only does this approach necessitate several visits to the hospital
for the initial injections or to collect the cells, but is also associated with a wide variety of side-
effects ranging from flulike symptoms to more severe conditions [4]. In contrast, intraopera-
tive cell therapies, in which cells are harvested from the patient prior or during the initial oper-
ation and then re-administered during the same surgical session, represent a new class of
exciting approaches that hold promise to overcome the high costs and many of the potential
drawbacks associated with ex vivo cell expansion, cytokine-based cell mobilization, and save
time for both patients and clinicians (Fig 1). Bone healing may be an ideal candidate to illus-
trate such a concept: in the US, approximately 7.9 million bone fractures are reported each
year with 5 to 10% resulting in an impaired bone-healing situation [5,6]. Predicting patients at
risk and initially providing them with additional treatment may significantly reduce the num-
ber of non-union cases and decrease the associated costs [7] and hospital stay [8].
For certain patients, harvesting autologous cells using an intraoperative setup, and enrich-
ing or depleting to obtain the appropriate cell population before delivery to the fracture loca-
tion may improve regeneration. Clinical approaches using CD34+ cells in critical limb
ischemia and in non-union treatment are already in place [9,10]. An intraoperative approach
to cell therapy was also reported for patients with ischemic cardiomyopathy, using CD133
+ cells derived from iliac crest aspirate [11], and in the context of bone regeneration using
marrow-derived connective tissue progenitors [12]. In both cases, positive cell isolation used
magnetic beads for cell separation, and these beads remained attached to the cells that were
transplanted. In both Europe and the USA, modification of transplanted cells, which includes
the use of antibodies or antibody-labeled beads that are not removed, may constitute more
than a minimal manipulation and would subsequently be classified as an advanced-therapy
medicinal product (ATMP), resulting in substantially greater regulatory burden for the pro-
cess. It is therefore of interest to develop new isolation procedures, for both positive and nega-
tive cell isolation that would be minimally manipulative to be potentially excluded from the
ATMP regulation. This would represent a platform technology for various intra-operative
approaches.
The aim of this project was to develop and prototype an approach to perform cell enrich-
ment using biophysically induced reversible cell binding. Whole blood was examined as the
cell source, since no additional invasive procedure would be necessary for the patient and it
could be done in parallel with a surgery. The initial target for this work is CD31, also known as
Platelet/Endothelial Cell Adhesion Molecule 1 (PECAM-1), cells, which have angiogenic, oste-
ogenic and immunosuppressive properties [13]. These cells have been used successfully in vivo
for treating ischemic vascular disease [14–16]. These cells are widely available, as 70 to 78% of
viable lymphocytes and monocytes express CD31 and their properties appear to be indepen-
dent of gender, and preserved with aging [13]. To achieve a positive selection approach that
yields a virtually "untouched" cell population (bead free, ligand free), we exploited reversible
binding of cells to aptamers. Aptamers are oligonucleotides that can bind a target with a high
specificity and yet, typically, a lower affinity than antibodies [17,18], and have minimal toxicity
[19]. They potentially offer competitive advantages over antibodies and other protein
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biologics, as they are stable under long-term storage at room temperature, can be easily chemi-
cally synthesized in a reproducible manner, and can be chemically manipulated with relative
ease. Aptamers have already been used in the clinic as therapeutics, and the first approved by
the FDA was an RNA aptamer directed against vascular endothelial growth factor (VEGF)-
165 for the treatment of neovascular (wet) age-related macular degeneration in 2004 [20]. This
approval paved the way for future approvals. In the current work, we validated a commercially
available aptamer as a promising candidate. We subsequently used it for reversible binding of
CD31+ cells, and report the development and optimization of a practical device and procedure
for the enrichment of CD31+ cells.
Materials and methods
PBMC preparation
For the initial studies, peripheral blood mononuclear cells (PBMCs) were obtained from aphe-
resis leukoreduction filters using traditional density centrifugation method. The Brigham and
Women’s hospital specimen bank provided the samples from consented patients. The cell sus-
pension was diluted with Dulbecco’s phosphate buffered saline (PBS) 1:1 before being layered
onto density centrifugation medium (Ficoll-paque plus, VWR, #17-1440-02) and centrifuged
for 30 min at 400 g without brake. The PBMCs layer was aspirated and rinsed twice at 200 g
for 8 min to remove platelets. PBMCs were then used for subsequent aptamer validation or
frozen for system optimization experiments. For magnetic bead studies and system validation,
fresh whole blood samples were purchased from Research Blood Components (Boston, MA)
Fig 1. General concept of intraoperative cell therapies and its application for bone fracture. While the
patient is being prepared for surgery or just after anesthesia, a blood sample is collected. Other sources such
as bone marrow, hematoma or tissue waste have also the possibility to be collected intraoperatively. In
parallel to the surgeon accessing the injury location (e.g. bone fracture), a specific cell population from the
sample is the target of enrichment or depletion. A general outline is illustrated using CD31+ cells as an
example. The desired fraction is then ready to be injected locally to promote a regenerative process. The
duration of the enrichment procedure should coincide to the time required to access the location of the injury.
https://doi.org/10.1371/journal.pone.0180568.g001
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and diluted with an equal volume of PBS + 2% fetal calf serum. PBMCs were obtained by fol-
lowing the manufacturer’s instruction with the Sepmate procedure (Stem Cell Technologies,
#15460).
Aptamer specificity
A commercially available biotinylated aptamer for CD31 was purchased (APTSCI, monola-
beled (only biotinylated) #CD31-2196BCI, bi-labeled (biotinylated and with additional Cy5)
#CD31-2196FBCI). To validate its specificity, PBMCs were resuspended at a concentration of
107 cells/ml. 100 ul of cells were incubated with the biotinylated aptamer at different concen-
trations for 30 min at 4˚C. Cells were then centrifuged for 5 min at 1200RPM and resuspended
in 100 ul flow cytometry staining buffer (eBioscience, #00-4222-26). Cells were stained for
CD31 (Alexa fluor 488, CD31, Biolegend, #303110) and biotin (PE anti-biotin antibody, Biole-
gend, #409004) before being analyzed on a BD LSRFortessa with HTS. For flow cytometric
analyses of the release kinetics of the biotinylated CD31 aptamer, a version bi-labeled with
additional fluorochrome Cy5 was used.
Magnetic bead studies
To benchmark our new approach, established and commercially available bead sorting strate-
gies were used as comparison. In certain studies, CD31+ cells were isolated by immunomag-
netic cell separation (MACS System; Milteny Biotec) according to the manufacturer’s
instruction using the CD31 Microbead kit (Milteny Biotec, #130-091-935). For the aptamer,
magnetic cell sorting was performed using a cell isolation kit for CD31+ cells (APTSCI,
#CD31-2196BCI) and following the manufacturer’s instruction.
In vitro characterization: Flow cytometry analysis. In order to analyze the different pop-
ulations, cells were resuspended in flow cytometry staining buffer at 107 cells/ml and stained
for CD14 (Biolegend, #325628), CD45 (Biolegend, #304006), CD31 (Biolegend, #303116),
CD3 (Biolegend, #300308) and CD19 (Biolegend, #302208) and analyzed on BD LSRFortessa.
For all analysis, the initial gating on PBMCs was performed using FSC and SSC parameters.
Subsequently, CD31+ levels were analyzed. To observe changes in naïve T cells, gating on CD3
+ cells was performed before analyzing changes in CD31+ levels. For the CD31+ cells compo-
sition, gating was performed on CD31+ cells and composition with regards to monocytes
(CD14+), T cells (CD3+) and B cells (CD19+) was evaluated.
System assembly
We chose to develop a tube based system for cell enrichment. Microcentrifuge tubes (Pierce,
#69705) served as the basis for the system. Using tweezers, polyethylene filters were removed
from the tubes. Then, biopsy punches (Sklar Instruments, #96–115) were used to extract 4 mm
diameter filters from 20 um cell strainers (Pluriselect, # 43-50020-03). A thin layer of cyanoac-
rylate glue (E-Z bond, #S-105) was applied to the base of the microcentrifuge tubes. The
punched-out filter was then applied to the base of the tube and pressed slightly using tweezers.
The system was then left to dry overnight at room temperature. Neutravidin agarose beads
were packed within the tube: neutravidin agarose beads (Piercenet, #29204) were diluted in
PBS with calcium and magnesium and filtered through a 100 um filter (Falcon, #352360).
Remaining beads in the filter were then collected. The beads solution was allowed to settle
before being resuspended in PBS. After a quick centrifugation step (1 min, 300 g), beads were
resuspended in a solution of biotinylated aptamers and incubated for 20 min at 4˚C. After
incubation, the tube was centrifuged and washed twice in PBS to remove unbound aptamer.
Two additional rinsing steps were performed before finally resuspending in 600 ul of binding
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buffer (APTSCI, #CD31-2196BCI) and transferring beads to the tube. In certain studies,
unmodified and aptamer coated beads were mixed and used in the columns. Luer-lock adap-
tors allowed these columns to be used with BD biosciences syringes.
Isolation procedure: From PBMCs to CD31+ enriched cell population
The PBMCs were run through the enrichment system at 50 ul/min, at a concentration of
2.5x107 cells/ml in binding buffer for 10 min. During that step, the whole system was kept ver-
tical during the duration of the experiment to alleviate issues related to cell sedimentation due
to the small diameter of 1ml syringes. Another 500 ul of binding buffer was then run through
at the same speed, before rinsing using 3 ml of PBS at 300 ul/min to remove unbound cells. An
infusion syringe pump was used to control the flow-rate (Braintree Scientific, #BS300). The
system was then disconnected from the syringe and beads were resuspended by sucking in and
out of 1ml syringe with an 18GA needle (VWR, KT868280-1801). This approach dispersed the
beads in solution and resulted in the release of the cells. The tube was centrifuged in a 2 ml
eppendorf tubes at 300 g for 3 min to collect the released cell population. Cell viability was
measured using the Muse1 Cell Analyzer.
Conditioned medium studies
Conditioned medium from the initial PBMCs population and released cell population was pre-
pared to assess their angiogenic and osteogenic potential. Cells were cultivated in EBM basal
medium (Lonza, #CC3121) supplemented with 2% fetal calf serum and 1% penicillin/strepto-
mycin (Biochrome) for the former and in DMEM low Glucose (Sigma-Aldrich) supplemented
with 10% fetal calf serum and 1% penicillin/streptomycin (Biochrome) for the latter. 1.2x106
cells were kept in 6 ml of medium over 24 hours. The medium was then sterile filtered and
stored at -20˚C until further experiments.
In-vitro: Angiogenic potential
The angiogenic potential of the cells was assessed using a tube formation assay. 96-well plates
were coated with 50 ul/well of Matrigel growth factor reduced (VWR, #354230) and trans-
ferred to a 37˚C cell culture incubator to allow the gel to solidify. In the meantime, a single cell
suspension of human umbilical vein endothelial cells (HUVECS, Lonza, #CC2519) between
passage 3 and 5, at 2x105 cells/ml was prepared. 50 ul of the cell suspension was added to each
well in culture medium without angiogenesis activators or inhibitors. Cells were allowed to
adhere for 20 minutes before adding 150 ul of conditioned medium. The plate was then incu-
bated overnight. Networks of cell structures were examined under a microscope and images
were taken at 10x. The total length of the network per image was evaluated using ImageJ and
divided by the results obtained for the HUVECS cultured in culture medium without angio-
genesis activators or inhibitors. For a positive control, the EGM bullet kit was used (Lonza,
#CC3124).
In-vitro: Osteogenic potential
Mesenchymal stromal cells were purchased from ATCC (#PCS-500-012). Cells from passage
3–4 were used for the experiments. In brief, 2.4x104 cells per well were seeded in a 96 well-
plate and cultivated in expansion medium for 24 hours before induction. Commercially avail-
able osteogenic differentiation medium (LifeTechnologies, #A10072-01) was purchased and
diluted 1:1 with conditioned media and 100 μl medium were applied to each well with
biweekly medium exchange. At the end of the study cell proliferation was evaluated using a
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redox-based metabolic assay (AlamarBlue Cell Viability Reagent, LifeTechnologies), and the
osteogenic differentiation visualized via Alizarin Red S staining (ARS). The stained wells were
rinsed repeatedly with PBS. Then, matrix-bound ARS was dissolved by addition of 10% cetyl-
pyridinium chloride before measuring absorption at 562nm. The resulting values were nor-
malized to the values obtained from alamar blue and divided by the values of the control cell
group cultured in regular osteogenic differentiation medium.
Results
Validation of aptamer as a suitable CD31+ cell enrichment candidate
The ability of an aptamer to bind CD31+ cells was initially confirmed by comparing suspended
cells labeled with the aptamer and a CD31 antibody. PBMCs were incubated with different
concentrations of the biotinylated aptamer before staining for both CD31 and biotin using
antibodies (Fig 2a). This analysis demonstrated that the aptamer was highly sensitive for the
CD31 population, with the sensitivity going up to 99.0±1.3% for an aptamer concentration of
5ug/ml (Fig 2b). In addition, the specificity was also really high with values between 96.9±4.1%
and 87.9±4.8 for aptamer concentration of 0.5 ug/ml and 5ug/ml respectively (Fig 2b).
To finish validating the aptamer, its capacity to concentrate CD31+ cells from a population
containing a mixture of CD31 positive and negative cells was evaluated. The aptamer was
coated onto magnetic beads (Ø = 1um) to allow capture of CD31+ cells (Fig 2c), and bench-
marked to a commercially available magnetic isolation bead separation approach. The apta-
mer-based isolation and commercial antibody isolation resulted in similar enrichment of
CD31+ cells.
Development of a cell enrichment system
The general principle of the system was as follows: PBMCs that contain a mixture of CD31-
and CD31+ cells were run through the system. The CD31+ cells adhered to the aptamer coated
beads while CD31- flowed through and were discarded. CD31+ cells were then released from
beads by imposing fluid shear with a simple mixing of the beads with attached cells and addi-
tional medium. Cells released were then collected by centrifugation (Fig 3a).
First we optimized the aptamer concentration for the coating of the beads. Increasing the
aptamer concentration resulted in an overall increase in the capture of cells (yield), as mea-
sured using a biophysically induced (flow release) and a subsequent DNAse based release (Fig
3b). In general no significant difference was observed between the initial cell viability and that
of flow-released cells (Fig 3c). However, at the highest aptamer concentration, flow-based sep-
aration did result in a decrease in cell viability after release, likely due to the overall stronger
avidity between the cells and these beads. To determine if adherent cells were retained after
intended release, we applied DNAse 1 to digest aptamers after flow release. The use of DNAse
1 significantly affected cell viability at all conditions and increasing aptamer concentration led
to an increase of retained cells (S1 Fig). Importantly, the flow based release strategy resulted in
an enrichment of CD31+ cells at a lower aptamer concentration but not at the highest aptamer
concentrations (S1 Fig). Therefore, subsequent steps for optimization were focusing on apta-
mer concentrations of 5 ug/ml and 10 ug/ml, as these provided an appropriate compromise
between cell yield, CD31+ purity and cell viability.
The next set of studies explored the impact of combining uncoated and aptamer coated
beads, and varying the total bead number in the columns. We employed a mixture of uncoated
beads and aptamer coated beads in the columns in the first studies, as the system sometimes
clogged in the earlier studies and we hypothesized this was due to cells binding throughout the
device. An equivalent yield to columns containing all coated beads was found with a 50:50 mix
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of coated:uncoated beads at the aptamer concentration of 5 ug/ml, but the yield was signifi-
cantly reduced at an aptamer concentration of 10ug/ml for the combination of uncoated and
coated beads (Fig 3d). However, there was no statistical difference using a 50:50 mix between 5
and 10ug/ml. Therefore, we use a 5ug/ml concentration for system validation. With the 50:50
mix, clogging was no longer observed, avoiding issues related to pressure building-up in the
system. The incorporation of uncoated beads also facilitated resuspension of the beads during
the cell recovery, although this effect was not quantified.
The final parameter optimized was the bead volume. An increasing cell yield was initially
obtained as the bead number was increased, until a saturation behavior was observed at 400 ul
of bead volume and above (Fig 3e). Importantly, microscopy-based observation of the cell pop-
ulation enriched with this system revealed none of the isolated cells contained bound beads.
System validation
The next studies quantified the ability of the optimized system to enrich CD31 cells from fresh
PBMCs derived from probands whole blood samples. The column used in these studies uti-
lized beads coated with 5 ug/ml of aptamer, a 50/50 ratio of coated to uncoated beads, and a
total bead volume of 800 ul (400 μl uncoated and 400 μl aptamer coated). The use of these
Fig 2. Aptamer validation with an antibody to CD31. a) Flow cytometry analysis for CD31 aptamer labeled
(y-axis, aptamer) and CD31 antibody labeled (x-axis, CD31+) cells among PBMCs at different aptamer
concentrations (Q1: Aptamer+CD31-, Q2: Aptamer+CD31+, Q3: Aptamer-CD31+, Q4: Aptamer-CD31-). The
aptamer concentration corresponds to the individual graph title. b) Specificity and sensitivity of the aptamer for
the CD31+ cells. Sensitivity was defined as the fraction of true positive (Aptamer+CD31+/CD31+). The
specificity was defined as the fraction of true negatives (Aptamer-CD31-/CD31-) (n = 3). c) Fraction of cell
population positively labeled with antibody to CD31 before (Initially) and after enrichment using traditional
magnetic beads strategies that were coated with CD31 antibody (MACS positive sorting) and CD31 specific
aptamer (Aptamer positive sorting). Beads were not released from cells prior to analysis. No significant
difference was observed in post-enrichment levels of CD31 for antibody and aptamer-mediated processes
(n = 4, Student’s-t-test). No error bar is visible for MACS positive sorting due to really similar high values.
Values in b, c represent mean and s.d.
https://doi.org/10.1371/journal.pone.0180568.g002
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columns resulted in a significant increase in the percentage of isolated cells that were CD31+,
from 64±9 to 87±3%, while retaining a high cell viability of 97±1% (Fig 4a). The yield of the
CD31+ cells was 25.1±0.9%. Further analysis revealed that the CD31+ fraction was signifi-
cantly enriched in monocytes (CD31+CD14+), as compared to the initial PBMC population
(Fig 4c). A significant increase in naïve T cells (CD3+CD31+) was also observed (Fig 4b). For
the precise gating strategy please refer to the material and methods section.
To confirm the previously reported regenerative potential of enriched CD31+ cells [13]
when obtained using the optimal column conditions, both an osteogenic and angiogenic in
vitro assay were utilized. An in vitro tube formation assay validated the increased angiogenic
potential of the enriched cell population; the total length of capillary-like tubes was increased
1.9±0.2 fold, as compared to the control condition (Fig 5a/5b, S3 Fig). The osteogenic potential
was also confirmed, as conditioned medium from enriched cells increased calcification by a
Fig 3. System development: Concept and optimization. a) Procedure for cell enrichment: (1) Cells are run
through the system at low velocity (50ul/min) to allow binding of CD31+ cells and removal of CD31- cells that
pass through the system unimpeded (2) Any remaining non-adherent cells are removed using PBS buffer
wash (300ul/min) (3) Cells are dissociated from beads by resuspension using a syringe. This results in
dissociation of the adherent cells from the beads (4) Tube is centrifuged immediately to collect desired cells
(CD31+) that were released from beads. b) Yield as function of aptamer concentration and release type (Flow
or DNAse 1 release). Yield was defined as the number of cells collected after enrichment divided by the
number of cells that went through the tube. All the beads were aptamer coated and 800ul of initial neutravidin
agarose bead solution was used per column. DNAse 1 was used at 500ug/ml for subsequent release (n = 3).
c) Effect of release type and aptamer concentration on cell viability (n = 3, data were analyzed using two-way
analysis of variance (ANOVA), * = P<0.05, **P<0.01) d) Effect of mixing uncoated beads and aptamer
coated beads on yield, for two aptamer concentrations (5 and 10ug/ml). Full indicates that all beads were
aptamer coated whereas 50/50 indicates that only half of the beads were aptamer coated (n = 3, data were
analyzed using one-way analysis of variance (ANOVA), * = P<0.05). e) Yield as a function of initial bead
volume suspension. An aptamer concentration of 10ug/ml was used for aptamer-coated beads. Data are
given as A+B where A is the volume of uncoated beads, and B is the volume of coated beads (n = 3, data
were analyzed using one-way analysis of variance (ANOVA), **P<0.01). Values in b, c, d and e represent
mean and s.d.
https://doi.org/10.1371/journal.pone.0180568.g003
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factor of 1.8±0.3 in MSCs, as compared to the control condition (Fig 5c/5d, S3 Fig). Further
data of control groups and analyses of the subpopulations have previously proven the high
regenerative potential of the total CD31+ population in vitro and in vivo [13], based on which
a simplified in vitro assessment was performed here.
Discussion
The goal of this study was to evaluate the potential of a cell sorting strategy that would allow to
sort for beneficial or detrimental cells from whole blood. Specifically, we aimed at developing
an approach for positive cell isolation that would result in a clean (bead free) cell population
enriched for a specified cell surface marker. We prototyped a system to perform biophysically
induced reversible binding and validated it using CD31+ cells as an example.
The commercial aptamer showed high sensitivity and specificity for CD31+ cells derived
from PBMCs. Flow cytometry data showed mainly double positive (CD31+ and Apt+) and
double negative populations (CD31- and Apt-) for cells isolated using aptamer concentrations
of 2ug/ml and above. Also, magnetic isolation bead separation resulted in similar enrichment
for aptamer and antibody based isolation. This is in agreement with recently published data
using the same aptamer to target another cell type expressing CD31; endothelial progenitor
cells were successfully isolated from a mixture with CD31- 293FT cells at a comparable level to
antibody isolation [21]. In this work, we validated the aptamer for the first time for PBMCs.
Cell release from this enrichment system was mediated solely by mechanical forces and did
not require the use of any additional chemicals that could contaminate the isolated cells. A
compromise between cell yield, CD31+ purity, and cell viability was found by adjusting
Fig 4. System validation using fresh whole blood samples. The experiments were performed using a
5ug/ml aptamer concentration with an initial volume of 800ul of neutravidin agarose beads. Half the beads in
columns were aptamer coated. a) The percentage of PBMCs that are CD31+, as indicated by antibody
staining and FACs analysis, before (PBMCs) and after enrichment using the aptamer-bead column system
(Released) b) Percentages of cells in the overall population that were CD3+CD31+ (naïve T cells), as
indicated by antibody staining and FACS analysis, before (PBMCs) and after enrichment (Released) c)
Composition of the CD31+ fraction according to antibody staining and FACS analysis before (PBMCs) and
after enrichment (Released) (n = 5, values in a and b represent mean and s.d., values in c represent mean,
data were analyzed using paired Student’s t-test, ** = P<0.01, ***P<0.001).
https://doi.org/10.1371/journal.pone.0180568.g004
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aptamer concentration, bead number and combining uncoated and aptamer coated beads. In
current commercial approaches, cell release from beads in antibody approaches utilizes an elu-
tion buffer, and antibodies remain attached to the cells. Whereas aptamers offer the possibility
of a reversible binding approach, strategies reported to date typically require exposure to the
aptamer complementary strand, enzymatic treatment [22], or use of a high concentration dex-
tran sulfate [20]. Chemical-free approaches to aptamer binding have been reported in which
the temperature and shear sensitivity of aptamer binding has been exploited in microfluidic
devices [23,24]. However, to the authors’ knowledge, this is the first report of reversible apta-
mer binding without the use of any chemical or temperature modification. As biological
bonds based on secondary interactions can be sensitive to applied stress [25–28], it is not sur-
prising that shear stresses induced by resuspending the beads can be sufficient to induce cell
release. Additionally, by resuspending the beads and separating them, there is a loss of the
avidity effect coming from multiple beads in contact with the cells and the affinity of individual
aptamer might be too weak to hold the cells for long. As some cells still remained attached to
the beads after shearing, as evidenced by their recovery with a subsequent DNAse step, higher
shear stresses could potentially release a greater number of CD31+ cells from the agarose
beads. However, increased shear could also lead to cell damage and loss of cell viability. The
aptamer affinity was reported to be significantly lower (Kd = 1.14x10^-9M) than the extremely
high affinity biotin-neutravidin linkage (Kd = 10^-14 M). Therefore, it is also reasonable to
assume that bead-free cells were also aptamer-free. This was confirmed using a bi-labeled ver-
sion of the biotinylated aptamer with additional fluorochrome Cy5 (S4 Fig). This approach
gave the possibility to analyze the cells once collected after enrichment, without having to do
any additional labeling step that might result in aptamers falling off or unspecific binding of
Fig 5. Angiogenic and osteogenic properties of released cell population. Conditioned medium was
prepared from cell populations enriched using a 5ug/ml aptamer concentration with an initial volume of 800ul
of neutravidin agarose beads. Half the beads were aptamer coated. a) HUVECs cultured in endothelial basal
medium without addition of angiogenesis activators (EBM medium) or with conditioned medium (50ul EBM
medium + 150ul conditioned medium) from released cell population (Released) were observed using bright
field microscopy. b) Relative tube length was calculated and defined as the mean total length of the network
for released samples divided by the results obtained for the HUVECS cultured in EBM medium. c) Alizarin red
staining of MSCs differentiated for two weeks in osteogenic medium (Osteo medium) or in conditioned
medium (½ osteogenic medium +½ conditioned medium, Released). d) Relative calcification was calculated
and defined as ratio between absorption values obtained by dissolution of matrix-bound ARS using 10%
cetylpyridinium divided by values obtained from alamar blue, and normalized to the values obtained for the
osteo medium group. (n = 5, scale bar = 200um). Values in b and d represent mean and s.d., data were
analyzed using paired Student’s t-test, **P<0.01, ***P<0.005).
https://doi.org/10.1371/journal.pone.0180568.g005
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the secondary antibody. Also, according to the manufacturer, there was no biophysical differ-
ences between the mono- and the bi-labeled aptamer.
Importantly, the released cell population with the system developed in this report is free of
beads, likely due to the size difference between the beads and the mesh size of the filter compo-
nent. Neutravidin agarose beads, with a diameter initially between 45 and 165 um, were fil-
tered through a 100 um cell strainer to select only larger size beads. Concerns from regulatory
offices often relate to the possibility of remaining beads in the final product, since most of the
cell sorting options currently available rely on beads in the nanometer to micrometer range.
However, the filters at the base of the tubes in the current system have a 20 um mesh size that
prevent bead passage, but was still adequate for leukocytes, since their diameter is between 6
and 10um [29,30]. The possibility of phagocytosis of immunobeads during positive cell isola-
tion is also a major concern [31], but is not an issue in our approach due to the fact that the
beads used here are several times larger than the cells creating a clear size separation between
cell and capturing beads as was also reported for other systems before [32].
The system leads to an enriched CD31+ cell population with increased angiogenic and oste-
ogenic potential. A particular enrichment in monocytes was noted, which is not surprising
since we observed that they had the highest level of CD31 expression among PBMCs. How-
ever, an increase in naive T cells also took place. In a previous study, a similar concept of selec-
tive enrichment was reported by Sass et al. but using the magnetic activated cell sorting [13].
The conditioned medium from the cell population enriched with this improved system led to
an increase in the total tube network length in an angiogenesis assay, and enhanced the osteo-
differentiation of MSCs. Those results are in agreement and have been already demonstrated
by Sass et al. for CD31+ enriched cell populations and the respective subpopulations [13].
Other studies have also shown that monocytes are involved in promoting bone formation
through non-immunological aspects either directly by cytokine secretion of osteogenic and
angiogenic factors, or indirectly by activating additional cells to also secret appropriate cyto-
kines [33,34]. However, angiogenic and osteogenic promotion are not exclusive to monocytes
among CD31+ cells, and the enrichment of naïve T cells may also underlie these effects.
Indeed, upon stimulation, CD31+ T cells had an increased secretion of angiogenic factors
(G-CSF, interleukin 8 and matrix metallopeptidase-9) compared to CD31- T and those cyto-
kines are highly involved in vessel development and damage response to tissue ischemia. [35].
This system has significant therapeutic potential. It is commonly accepted that 106 PBMCs/
ml can be isolated from blood [36]. This would imply that with the current approach, approxi-
mately 15.8 million enriched CD31+ cells could be collected from 100 ml of blood, which is a
reasonable blood draw. Further development of this system could also allow it to be utilized to
target other surface antigens for either enrichment or depletion. Methods to generate an apta-
mer to a target of interest have been previously reported [37], and allow for the in vitro evolu-
tion of nucleic acid molecules with highly specific binding to target molecules. To utilize this
system to deplete undesirable cell populations, one could simply use agarose beads coated with
an appropriate antibody or aptamer to remove these cells from a mixed population; in this
approach, the desirable cells would be those that initially pass through the system. One target
for selective depletion could be CD8+ T cells, as they have been shown to have a negative
impact on the bone healing process [38]. Coating the agarose beads with a biotinylated anti-
body for CD8+ allowed depletion of those cells from a starting PBMCs population (S2 Fig).
One could also combine a series of these separations, allowing both positive and negative selec-
tions to be integrated into one system.
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Supporting information
S1 Fig. a) Percentages of cells in the overall PBMCs population that were CD31+, as indicated
by antibody staining and FACs analysis, as a function of aptamer concentration and release
type (Flow or DNAse1 release). CD31+ levels were compared before (Initially) and after proce-
dure at two aptamer concentrations (10 and 50ug/ml) for the two releases (Flow or DNAse 1).
b) Impact of procedure on cell viability. Cell viability as determined by Muse1 Cell Analyzer,
was evaluated in the initial PBMCs population (Initially) and in released cell population at two
aptamer concentrations (10 and 50ug/ml) for the two releases (Flow or DNAse 1), n = 3. Data
were analyzed using one-way analysis of variance (ANOVA). All beads were aptamer coated
for this experiment.
(TIF)
S2 Fig. Adaptation of the system towards cell depletion by coating beads with a biotiny-
lated CD8 antibody instead of a CD31 aptamer. Beads were incubated for 20 min at 4˚C
with a biotin anti-human CD8 antibody (Biolegend, #344720). PBMCs were run through the
system and non-adherent cells collected and analyzed. Histograms from FACS analysis for
CD8+ cells, determined using antibody to CD8, in both the original cell population (PBMCs)
and collected cells (Depleted population).
(TIF)
S3 Fig. Biological properties of released cell population. Conditioned medium was prepared
from PBMCs and enriched CD31+ cells using a 5ug/ml aptamer concentration with an initial
volume of 800ul of neutravidin agarose beads. Half the beads were aptamer coated. a) Relative
tube length was calculated and defined as the mean total length of the network formed by
HUVECS cultured under conditioned medium derived from PBMCs and Released (CD31+)
cells (n = 5), normalized to the values obtained for the HUVECS cultured in EBM medium
without growth factor addition (indicated as dotted line). EBM medium plus additional
growth factors (EBM bullet Kit, Lonza) served as a positive control. CD31+ released cells had a
significant higher impact on angiogenic tube formation than the whole PBMC fraction b)
Impact on osteogenic differentiation and matrix calcification was calculated and defined as the
ratio between absorption values obtained by dissolution of matrix-bound ARS using 10%
cetylpyridinium divided by values obtained from alamar blue, and normalized to the values
obtained for the osteo medium group (n = 3). DMEM Expansion medium containing 10%
FCS served as a negative control, DMEM diluted with osteo medium, eventually containing
5% FCS served as FCS adapted control. Values in a and b represent mean and s.d., data was
analyzed using Anova-One way with Bonferroni’s comparison of selected groups,  significant
to control, # significant to Released CD31+, P<0.05, P<0.01, /###P<0.005).
(TIF)
S4 Fig. Release of the aptamer. Flow cytometric analyses after cell enrichment using a
Cy5-coupled version of the biotinylated aptamer were performed. Cells were analyzed before
processing as negative control, the released cells were analyzed prior to a re-newed staining to
show that none of the Cy5-fluorochrome-coupled aptamer remained on the cells and then re-
stained and analyzed again to evaluate the median fluorescence intensity of aptamer coupled
cells. The Histogram in a) shows representative data from 1 patient. The orange line represents
the unprocessed, unstained sample as a negative reference (median fluorescence intensity 21
AU). The red line represents the fluorescence intensity of the released cell population (median
fluorescence intensity 52,4 AU), the blue line shows the median fluorescence intensity after
renewed staining with the Cy5-fluorochrome-couple aptamer after processing (median fluo-
rescence intensity 1044 AU), b) shows the average median fluorescence intensity (MFI) from
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before and after the enrichment of cells (negative reference MFI 42,6 ± 18,77 AU, released cell
population MFI 31,13 ± 18,42 AU, released and re-stained MFI 939 ± 167,36 AU) (n = 3,
P<0.0001, Anova-One way with Bonferroni’s comparison).
(TIF)
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